|
a1
|
4.3992 × 10−2
|
Panc02 tumor growth rate
|
\( \frac{1}{day} \)
|
Estimated
|
|
Cmax
|
1 × 1010
|
Maximum sustainable tumor cell population
|
cell
|
[19]
|
|
b1
|
3.23 × 10−7
|
NK-mediated tumor cell kill rate
|
\( \frac{1}{cell\times day} \)
|
[19]
|
|
c1
|
1.1 × 10−7
|
CTL-mediated tumor cell kill rate
|
\( \frac{1}{cell\times day} \)
|
[19]
|
|
d1
|
2 × 10−34
|
Proportional parameter of anti-CD25 treatment for inhibition of anti-immune effects of Treg on CTL-mediated tumor cell killing
|
\( \frac{1}{cell^3} \)
|
Estimated
|
|
e1
|
0.345
|
Rate of the suppressive effect of Treg on CTL-mediated tumor cell killing
|
\( \frac{1}{cell} \)
|
[34]
|
|
f1
|
0.286
|
Rate of the suppressive effect of TGF-β on CTL-mediated tumor cell killing
|
\( \frac{ml}{ng} \)
|
[34]
|
|
g1
|
3.5 × 10−2
|
The apoptosis rate of Panc02 tumor cells by low-dose 5-FU treatment
|
\( \frac{1}{day} \)
|
Estimated
|
|
h1
|
2.5 × 105
|
Proportional parameter of tumor inhibition rate by Treg depletion through anti-CD25 treatment
|
\( \frac{cell}{day} \)
|
Estimated
|
|
k1
|
1 × 10−15
|
Proportional parameter of tumor inhibition rate by Treg depletion through anti-CD25 treatment
|
\( \frac{1}{cell} \)
|
Estimated
|
|
l1
|
100
|
Depth of access of immune cells to the tumor mass
|
\( {cell}^{\frac{1}{3}} \)
|
[19]
|
|
a2
|
1.4 × 104
|
Constant generation source of NK cells
|
\( \frac{cell}{day} \)
|
[19]
|
|
b2
|
4.12 × 10−2
|
The exponential death rate of NK cells
|
\( \frac{1}{day} \)
|
[19]
|
|
c2
|
0.125
|
Maximum of IL-2-mediated NK cell growth
|
\( \frac{1}{day} \)
|
[34]
|
|
d2
|
0.3
|
Steepness coefficient of the IL-2-mediated NK cell growth rate
|
\( \frac{ng}{ml} \)
|
[34]
|
|
e2
|
0.125
|
Maximum of IFN-γ mediated NK cell growth rate
|
\( \frac{1}{day} \)
|
[34]
|
|
f2
|
0.3
|
The steepness coefficient of the IFN-γ-mediated NK cell growth rate
|
\( \frac{ng}{ml} \)
|
[34]
|
|
g2
|
1 × 10−9
|
Inactivation rate of NK cells by tumor cells
|
\( \frac{1}{day} \)
|
Estimated close to the value reported in [19]
|
|
h2
|
1 × 10−10
|
Suppression rate of NK cells by Tregs.
|
\( \frac{1}{cell\times day} \)
|
[34]
|
|
a3
|
2 × 10−2
|
The exponential death rate of CTLs
|
\( \frac{1}{day} \)
|
[19]
|
|
b3
|
8 × 10−2
|
Maximum tumor-mediated CTL recruitment rate
|
\( \frac{1}{day} \)
|
Estimated close to the value reported in [19]
|
|
c3
|
2.02 × 1014
|
Steepness coefficient of the tumor-mediated CTL recruitment curve
|
cell2
|
Estimated with regarding the value reported in [19]
|
|
d3
|
1.1 × 10−7
|
CTL stimulation rate by tumor-NK cells interactions
|
\( \frac{1}{cell\times day} \)
|
[19]
|
|
e3
|
1.5 × 10−10
|
Inactivation rate of CTLs by tumor cells
|
\( \frac{1}{cell\times day} \)
|
Estimated close to the value reported in [19]
|
|
f3
|
125 × 10−5
|
Maximum of IL-2-mediated CTL growth rate
|
\( \frac{1}{day} \)
|
Estimated with regarding the value reported in [34]
|
|
g3
|
0.3
|
The steepness coefficient of the IL-2-mediated CTL growth rate
|
\( \frac{ng}{ml} \)
|
[34]
|
|
h3
|
12.5 × 10−2
|
Maximum of IFN-γ-mediated CTL growth rate
|
\( \frac{1}{day} \)
|
[34]
|
|
k3
|
0.3
|
The steepness coefficient of the IFN-γ-mediated CTL growth rate
|
\( \frac{ng}{ml} \)
|
[34]
|
|
l3
|
1 × 10−10
|
Suppression rate of CTLs by Tregs
|
\( \frac{1}{cell\times day} \)
|
[34]
|
|
p3
|
2.5 × 106
|
The normal number of splenic MDSCs in C57/BL6 mice
|
cell
|
[19]
|
|
m3
|
18 × 10−2
|
Minimal CTL proliferation factor induced by inhibition of MDSCs
|
---
|
[19]
|
|
n3
|
6 × 10−3
|
Parameter for MDSC-induced inhibition of CTL proliferation
|
\( \frac{1}{cell^2} \)
|
[19]
|
|
a4
|
1.25 × 106
|
Normal MDSC production rate
|
\( \frac{cell}{day} \)
|
[19]
|
|
b4
|
3.25 × 10−2
|
MDSCs normal death rate
|
\( \frac{1}{day} \)
|
Estimated with regarding the value reported in [19]
|
|
b4
|
8 × 10−2
|
MDSCs death rate during 5-FU treatment
|
\( \frac{1}{day} \)
|
Estimated with regarding the value reported in [19]
|
|
c4
|
0.7 × 107
|
MDSC expansion coefficient in Panc02 tumor-bearing mice
|
\( \frac{cell}{day} \)
|
[19]
|
|
d4
|
1 × 1010
|
Steepness coefficient of the tumor-mediated MDSC production curve
|
cell
|
[19]
|
|
a5
|
3.6 × 105
|
The production rate of T helper cells in the thymus
|
\( \frac{cell}{day} \)
|
[34]
|
|
b5
|
1.2 × 10−3
|
The exponential death rate of T helper cells based on the half-life
|
\( \frac{1}{day} \)
|
[34]
|
|
c5
|
0.125
|
Maximum IL-2-mediated T helper cell proliferation rate
|
\( \frac{1}{day} \)
|
[34]
|
|
d5
|
0.3
|
Steepness coefficient of the IL-2-mediated T helper cell proliferation curve
|
\( \frac{ng}{ml} \)
|
[34]
|
|
e5
|
0.125
|
Maximum IFN-γ-mediated T helper cell proliferation rate
|
\( \frac{1}{day} \)
|
[34]
|
|
f5
|
0.3
|
Steepness coefficient of the IFN-γ-mediated T helper cell proliferation curve
|
\( \frac{ng}{ml} \)
|
[34]
|
|
g5
|
1 × 10−10
|
Suppression rate of T helper cells by Tregs
|
\( \frac{1}{cell\times day} \)
|
[34]
|
|
a6
|
5.6 × 105
|
The constant production rate of Tregs
|
\( \frac{cell}{day} \)
|
[34]
|
|
b6
|
2.3 × 10−2
|
The exponential death rate of Tregs based on the half-life
|
\( \frac{1}{\ day} \)
|
[34]
|
|
c6
|
2 × 10−4
|
Treg origination rate from CTLs
|
\( \frac{1}{\ day} \)
|
[34]
|
|
d6
|
4 × 10−4
|
Treg origination rate from T helper cells
|
\( \frac{1}{\ day} \)
|
[34]
|
|
e6
|
0.125
|
Maximum IL-2-mediated growth rate of Tregs
|
\( \frac{1}{day} \)
|
[34]
|
|
f6
|
0.3
|
Steepness coefficient of the IL-2-mediated Treg growth curve
|
\( \frac{ng}{ml} \)
|
[34]
|
|
g6
|
1 × 10−11
|
NK-mediated Treg degradation constant rate
|
\( \frac{1}{cell\times day} \)
|
[34]
|
|
h6
|
1.5 × 10−11
|
Constant inhibition rate of Tregs by anti-CD25 treatment
|
\( \frac{1}{\ day} \)
|
[34]
|
|
\( \frac{{\boldsymbol{\tau}}_{\mathbf{1}}}{{\boldsymbol{\alpha}}_{\mathbf{1}}} \)
|
2.2483 × 1011
|
The natural death rate of IL-2 based on its half-life/ constant production rate of IL-2 by T helper cells
|
\( \frac{cell\times ml}{ng} \)
|
[34]
|
|
\( \frac{{\boldsymbol{\beta}}_{\mathbf{1}}}{{\boldsymbol{\tau}}_{\mathbf{2}}} \)
|
4.4691 × 10−13
|
constant production rate of IFN-γ by CTLs/ Natural death rate of IFN-γ based on its half-life
|
\( \frac{ng}{ml\times cell} \)
|
[34]
|
|
\( \frac{{\boldsymbol{\beta}}_{\mathbf{2}}}{{\boldsymbol{\tau}}_{\mathbf{2}}} \)
|
4.4691 × 10−13
|
The secretion rate of IFN-γ by NK cells/degradation rate of IFN-γ based on its half-life
|
\( \frac{ng}{ml\times cell} \)
|
[34]
|
|
\( \frac{{\boldsymbol{\beta}}_{\mathbf{3}}}{{\boldsymbol{\tau}}_{\mathbf{2}}} \)
|
4.4691 × 10−13
|
The secretion rate of IFN-γ by T helper cells/degradation rate of IFN-γ based on its half-life
|
\( \frac{ng}{ml\times cell} \)
|
[34]
|
|
\( \frac{{\boldsymbol{\lambda}}_{\mathbf{1}}}{{\boldsymbol{\tau}}_{\mathbf{3}}} \)
|
8.9382 × 10−13
|
The constant production rate of TGF-β by tumor cells/death rate of TGF-β based on its half-life
|
\( \frac{ng}{ml\times cell} \)
|
[34]
|
